Enterprise Value
-3.362M
Cash
32.29M
Avg Qtr Burn
-5.647M
Short % of Float
1.29%
Insider Ownership
36.42%
Institutional Own.
20.07%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EQ001 (Itolizumab) (monoclonal antibody that targets CD6-ALCAM) Details Acute graft-versus host disease | Phase 3 Interim Update | |
EQ001 (Itolizumab) Details Ulcerative colitis | Phase 2 Update | |
EQ101 Details Celiac disease, Alopecia areata | Phase 2 Update | |
EQ001 (Itolizumab)(monoclonal antibody that targets CD6-ALCAM) Details Systemic lupus erythematosus, Lupus nephritis | Phase 1b Update | |
Failed Discontinued | ||
EQ102 Details Celiac disease | Failed Discontinued |